The authors review the angiopoietin pathway as an alternative for safer and more efficacious anti-angiogenic therapeutics.
Rathin C. Das, PhD
Advertisement
Rathin Das, PhD, MBA, is chief executive officer of Synergys Biotherapeutics, 1945 Arbol Grande, Walnut Creek, CA 94595, rathindas2009@gmail.com
Articles by Rathin C. Das, PhD
Innovative products and a range of indications drive the therapeutic antibody market.
Advertisement
Latest Updated Articles
Angiopoietins: Novel Targets for Anti-angiogenesis TherapyPublished: October 1st 2013 | Updated:
Therapeutic Antibodies in ReviewPublished: February 1st 2013 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
$1.8M RedHill Deal Highlights Growing Worldwide Focus on H. pylori Treatment Access
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
